Маалокс®

General characteristics. Structure:

Active agents: magnesium hydroxide (in the form of gel) 600,00 mg;
Aluminum hydroxide (in the form of gel) 525,00 mg.
Excipients: Acidum hydrochloricum concentrated citric acid monohydrate, a peppermint of leaves oil, Mannitolum, methylparahydroxybenzoate, пропилпарагидроксибензоат, sodium saccharinate, sorbitol (70%), hydrogen peroxide (30%), the water purified.
Description: the white, or almost white, reminding milk liquid with a mint smell.

Pharmacological properties:

Pharmacodynamics. Aluminum hydroxide and magnesium hydroxide neutralize free hydrochloric acid of a gastric juice, without causing its secondary hypersecretion. Besides, increase рН a gastric juice at administration of drug of Maaloks® leads to decrease of the activity of pepsin in a gastric juice. Drug possesses also adsorbing and enveloping action thanks to which impact of disturbing factors on a mucous membrane of a gullet and a stomach decreases.

Pharmacokinetics. Magnesium hydroxide and aluminum hydroxide are considered as antacids of local action. Because of low absorption have no systemic action.

Indications to use:

- A peptic ulcer of a stomach and duodenum in an aggravation phase.
- Acute gastroduodenit, chronic gastroduodenit with the normal or increased secretory function in an aggravation phase.
- Hernia of an esophageal opening of a diaphragm, reflux esophagitis.
- The dispeptic phenomena, such as discomfort or pains in epigastriums, heartburn, an acid eructation after errors in a diet, the excess use of ethanol, coffee, nicotine, etc.
- The dispeptic phenomena, such as discomfort or pains in epigastriums, the heartburn, an acid eructation resulting from use of some medicines (non-steroidal anti-inflammatory drugs, glucocorticosteroids, etc.) and their prevention.

Route of administration and doses:

Маалокс accept usually in 1-1,5 h after food or during the developing of pains, Maaloks in the form of suspension accept 15 ml (1 package). Before the use to homogenize suspension, carefully kneading a package between fingers. To squeeze out contents of a package in a spoon or in a mouth.
To children the dosage is defined by the attending physician. If necessary it is possible to accept an additional dose of drug in two hours after the previous reception, but no more than 6 receptions a day.

Features of use:

If during treatment symptoms from digestive tract remain within more than 10 days or the aggravation of symptoms is observed, then it is necessary to specify the diagnosis and to carry out correction of medical actions. It is necessary to observe a 2-hour interval between use of the drug Maaloks® and other drugs and a 4-hour interval between administration of drug of Maaloks® and ftorkhinolon (watch "Interaction with other medicines"). In spite of the fact that drug is released without recipe, before use of drug during pregnancy and a lactation (breastfeeding), and also at teenagers and patients with a renal failure easy and moderate severity it is recommended to consult with the doctor.
It is necessary to avoid long purpose of the drug Maaloks® pass at renal failures. At purpose of the drug Maaloks® pass to patients with a renal failure easy and moderate severity needs to control carefully plasma concentration of aluminum and magnesium, and in case of their increase use of drug has to be immediately stopped. Algeldrat at the low content of phosphates in food can lead to development of insufficiency of phosphorus in an organism. Therefore at its use, especially long, it is necessary to provide sufficient intake of phosphates with food. Influence on ability to control of vehicles and work with mechanisms
Drug does not influence ability to control of vehicles and work with mechanisms.

Side effects:

At observance of the recommended dosing mode side effects meet seldom.
There can sometimes be diarrhea, a lock, nausea, vomiting, change of flavoring feelings.
At long reception of high doses can arise a hypophosphatemia (especially at the low content of phosphates in food), a hypercalcuria, a nephrocalcinosis, a hypocalcemia, osteoporosis, osteomalacy, a renal failure. At patients with a renal failure are possible: increase in plasma concentration of magnesium and/or aluminum, thirst development, lowering of arterial pressure, hyporeflexia.
At prolonged use of high doses at patients a renal failure development of encephalopathy, dementia, microcytic anemia is in rare instances possible.

Interaction with other medicines:

- Skhinidin. At simultaneous use with quinidine increase in serumal concentration of quinidine and development of overdose of quinidine is possible.
- With acetylsalicylic acid (and other salicylates), blockers of N — histamine receptors, propranolol, atenololy, metoprololy, chloroquine, diflunisaly, digoxin, bisfosfonata, Ethambutolum, an isoniazid, ftorkhinolona, sodium fluoride, glucocorticosteroids (it is described for Prednisolonum and dexamethasone), indometacin, lansoprazoly,
linkozamidam, sodium left thyroxine, ketokonazoly, sodium polystyrenesulphate, Penicillaminum, iron salts, tetracyclines, fenotiazinovy neuroleptics, phosphorus food to additives, feksofenadiny.
At a concomitant use with the tablets Maaloks® absorption of the listed above drugs in digestive tract decreases. In case of a 2-hour interval between reception of these drugs and the tablets Maaloks® and a 4-hour interval between reception of ftorkhinolon and the tablets Maaloks® in most cases this undesirable interaction can be avoided.
- With salicylates (the cm is higher)
At a concomitant use of salicylates and the drug Maaloks® excretion of salicylates with urine as a result of alkalization of urine under the influence of the drug Maaloks® increases.
- With citrates
At an aluminum hydroxide combination to citrates increase in plasma concentration of aluminum, in particular, at patients with a renal failure is possible.

Contraindications:

- Heavy renal failure.
- Hypersensitivity to drug components.
- Deficit of invertase/isomaltase, intolerance of fructose, glyukozo-galaktozny malabsorption (because of existence in composition of drug of sorbitol).
- Children's and teenage age up to 15 years.
- Hypophosphatemia.
If at you one of the listed diseases or states before administration of drug surely consult with the doctor. With care
- At a renal failure (at administration of drug of Maaloks® at such patients increase in plasma concentration of magnesium and aluminum is possible; and at prolonged use of the drug Maaloks® in high doses including in high therapeutic doses, development of encephalopathy, dementia, microcytic anemia is possible).
- At the patients with a porphyria who are on a hemodialysis.
- At pregnancy and in the period of a lactation (see. "Pregnancy and period of a lactation").
- At Alzheimer's disease.
- At the low content of phosphates in food (risk of development of phosphatic insufficiency).
If at you one of the listed diseases or states before administration of drug surely consult with the doctor. Pregnancy and period of a lactation Pregnancy
At animals accurate instructions on existence of teratogenic effect at aluminum of hydroxide and magnesium of hydroxide are not received. Currently no specific teratogenic effects when using the drug Maaloks® are revealed during pregnancy, however in connection with insufficiency of clinical experience of its use during pregnancy perhaps, only if the potential advantage of its use for mother justifies potential risk for a fruit. Lactation period
During administration of drug of Maaloks® of the termination of feeding the breast does not require.

Overdose:

 

 

Storage conditions:

To store at a temperature not above 25 °C. To store in the place, unavailable to children! Period of storage 3 years. Not to use drug after the period of validity specified on packaging!

Issue conditions:

Without recipe

Packaging:

Suspension for intake in bags (sachet), 15 ml.
On 15 ml of drug place in bags (sachet) from paper / the aluminum foil laminated by polyethylene. On 30 bags (sachet) together with the application instruction place in a cardboard pack.